A new series of 2-substituted-5-{2-[(2-halobenzyl)thio)phenyl}-1,3,4-
Introduction
Benzodiazepine (BZD) receptor ligands allosterically modulate the action of GABA on neuronal chloride ion flux, thus eliciting a wide variety of pharmacological actions ranging a continuum from full agonists (anxiolytic, sedative/hypnotic, and anticonvulsant activities) to inverse agonists (proconvulsant and anxiogenic activities), and antagonists, which do not exhibit any pharmacological effects but can antagonize the action of both agonists and inverse agonists [1] [2] [3] . The BZD binding sites in the brain were identified and described by radioligand receptor binding assays and originally it was found that only 1,4-BZD derivatives bind to these receptors. It has since been shown that many groups of compounds bind to the BZD receptor with high affinity, e. g., triazolopyridazines, cyclopyrrolones, quinolines and β-carbolines [4] [5] [6] [7] . Several pharmacophore models have been proposed for BZDs, and amongst all models suggested for binding to the BZD receptor at least two features are common: an aromatic ring and a coplanar proton accepting group in suitable distance (5A o ). Also, the presence of a second out-ofplane, aromatic ring could potentiate binding to the receptor [8] [9] [10] [11] [12] . On this basis, a wide variety of compounds with a chemical structure different from that of benzodiazepines have been synthesized and tested. We recently started a wide research program aimed to design new BZD receptor ligands characterized by a higher degree of flexibility compared with classic BZD ligands. Accordingly, we reported several 1,3,4-oxadiazole derivatives which showed considerable anticonvulsant activity [13] [14] [15] . As part of our ongoing research program to design new anticonvulsant agents, we describe herein the synthesis and biological 
Results and Discussion

Chemistry
The target 1,3,4-oxadiazole derivatives were synthesized according to 
Pharmacology
The BZD activity of the synthesized compounds was determined through the evaluation of the ability of the compounds to protect mice against convulsion induced by a lethal dose of PTZ and electroshock as two routine models. Diazepam was considered as a reference BZD agonist with anticonvulsant effect in both models. As shown in Table 2 , compound 3a with an amino group on position 2 of the oxadiazole ring and a fluoro subtituent at ortho position of the benzylthio moiety has the best anticonvulsant activity in both PTZ and MES models. The activity was antagonized with flumazenil, a benzodiazepine antagonist, which establishes the involvement of benzodiazepine receptors in this effect. Figure 2 shows the superimposition of energy minima conformers of the compound 3a, the most potent synthesized analogues, and estazolam. Obviously, the main BZD pharmacophores, aromatic rings and proton accepting groups (π1 interaction), nitrogen (N-3) of the 1,3,4-oxadiazole and triazolobenzodiazepine rings, are well matched.
Fig. 2.
Replacement of the fluoro substituent with a larger electron-withdrawing group such as Cl (3b) decreases the activity which may be explained by a steric hindrance effect. These results are in good agreement with the classical SAR data of BZDs [22] and our previous studies on 1,3,4-oxadiazoles [14, 15] . In the series of 2-alkylthio oxadiazoles, compounds 5a and 5b possessing a small alkylthio group at C-2 of the 1,3,4-oxadiazole ring had good anticonvulsant activity in the MES Synthesis and Pharmacological Evaluation of New … 191 model but showed mild activity against PTZ induced convulsion. Increasing the size of the alkyl group (5c and 5f) significantly decreases the anticonvulsant activity in both PTZ and MES models. Accordingly, compounds 5e and 5f with a bulky benzylthio group did not show any anticonvulsant effects. Similarly, compounds 7a
and 7b did not have any considerable anticonvulsant activity in both models.
Therefore, the size and nature of groups at C-2 position of 1,3,4-oxadiazole ring are very important for anticonvulsant activity in both PTZ and MES models. In addition, the size of electron withdrawing substituents at ortho position of the benzylthio moiety is also important for their anticonvulsant effects. 
General procedure for preparation of 2-[(2-Halobenzyl)thio]benzoic acid hydrazides 2
To a solution of 2-[(2-halobenzyl)thio]benzoic acid methyl ester 1 (10 mmol) in DMF (10 ml), hydrazine hydrate (50 mmol) was added and stirred at room temperature for 10 hours. After this time, 100 ml water was added and the solid thus separated was filtered, dried and recrystallized from ethanol [16] . To a methanolic solution of 2 (5.1 mmol), cyanogens bromide (7.5 mmol) was added. The reaction mixture was stirred at room temperature for 3 hours. The resulting solution was neutralized with sodium bicarbonate solution. The solid thus separated out was filtered, washed with water, dried and recrystallized from ethanol [17] .
2-Fluoro-2-benzylthio benzoic acid hydrazide (2a)
Yield
5-{2-[(2-Fluorobenzyl)thio]phenyl}-1,3,4-oxadiazol-2-amine (3a)
Yield 
5-{2-[(2-Chlorobenzyl)thio]phenyl}-1,3,4-oxadiazol-2-amine (3b)
General procedure for preparation of 5-{2-[(2-Halobenzyl)thio]phenyl}-1,3,4-oxadiazole-2-thiols 4
A mixture of 2 (3.6 mmol), KOH (10 mmol) and carbon disulfide (10 mmol) in ethanol (10 ml) was refluxed on a steam bath for 12 hours. The solution was then concentrated, cooled and acidified with dilute HCl. The solid product that separated was filtered, washed with cold ethanol, dried and recrystallized from ethanol [18] . 
5-{2-[(2-Fluorobenzyl)thio]phenyl}-1,3,4-oxadiazole-2-thiol (4a)
General procedurefor preparation of 5-(Alkylthio)-2-{2-[(2-halobenzyl)thio]phenyl}-1,3,4-oxadiazoles 5
An ethanolic solution of appropriate alkyl iodide (3.0 mmol) was added to a solution of compound 4 (2.4 mmol) in 10% aqueous sodium hydroxide (5 ml), and the mixture was sonicated in a sonication bath for 30-60 minutes. The reaction mixture was poured into cold water (50 ml) and the solid thus separated was filtered, washed with water, dried and recrystallized from ethanol [19] . 
2-{2-[(2-Fluorobenzyl)thio]phenyl}-5-(methylthio)-1,3,4-oxadiazole (5a)
2-{2-[(2-Chlorobenzyl)thio]phenyl}-5-(methylthio)-1,3,4-oxadiazole (5b)
2-{2-[(2-Chlorobenzyl)thio]phenyl}-5-(ethylthio)-1,3,4-oxadiazole (5d)
Pharmacology
Anticonvulsant evaluation of the synthesized compounds was performed following the standard procedure provided by the antiepileptic drug development program [23, 24] . It includes qualitative assays using MES and PTZ tests. 
Statistical analysis
Statistical analysis of the anticonvulsant activity of the synthesized compounds on animals was evaluated using a one-way analysis of variance (ANOVA). In all cases, post-hoc comparisons of the means of individual groups were performed using Fisher's Exact Probability test. Differences with P< 0.05 between experimental groups at each point were considered statistically significant. All values were expressed as mean ± SD (standard deviations). For statistical analysis 
Conclusions
The results of this investigation indicate that 1,3,4-oxadiazoles having an amino group at C-2 position with a benzylthio moiety possessing a suitable ortho electron withdrawing substituent can show moderate benzodiazepine activity confirming the suggested SARs for benzodiazepine agonists.
